Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects

Atherosclerosis

Volumn 162, Issue 2, 2002, Pages 381-389

  Rahmani, Maziar ^a   Raiszadeh, Farbod ^a   Allahverdian, Sima ^a   Kiaii, Shahryar ^a   Navab, Mohamad ^b   Azizi, Fereidoun ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apolipoproteins; Coronary artery disease; Diabetes mellitus; Lipids; Lipoproteins; Paraoxonase

Indexed keywords

4 NITROPHENOL; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PARAOXON; PHENOL; PHENYLACETIC ACID; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DIET RESTRICTION; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; IMMUNOASSAY; IRAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPECTROPHOTOMETRY; TRIACYLGLYCEROL BLOOD LEVEL; TURBIDIMETRY;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; ESTERASES; FEMALE; HUMANS; IRAN; LIFE STYLE; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; REFERENCE VALUES;

EID: 0036242261     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00715-8     Document Type: Article

References (55)

1. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study
2. Diabetes and atherosclerosis: An epidemiologic view
3. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction
4. Diabetes and cardiovascular disease. The Framingham study
5. Lipoprotein metabolism in diabetes mellitus
6. Plasma levels of apolipoprotein A-I and apolipoprotein B in human atherosclerosis
7. The association of serum lipids, lipoproteins, and apolipoproteins with coronary artery disease assessed by coronary arteriography
8. Apolipoproteins A-I and B as predictors of angiographically defined coronary artery disease
9. Are apolipoproteins better discriminators than lipids for atherosclerosis?
10. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins
11. Apolipoproteins and coronary artery disease
12. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease
13. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study
14. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study
15. Optimized automated apolipoprotein A-I assays as markers for coronary artery disease
16. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI
17. DNA inversion within the apolipoproteins AI/CIII/AIV-encoding gene cluster of certain patients with premature atherosclerosis
18. Familial apolipoprotein A-I, C-III, and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11
19. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease
20. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study
21. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture
22. Interethnic differences of human serum paraoxonase activity-relevance for the detoxification of organophosphorous compounds
23. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus
24. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins
25. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus
26. Human serum paraoxonase
27. Serum paraoxonase activity and phenotype distribution in Turkish subjects with coronary heart disease and its relationship to serum lipids and lipoproteins
28. Selective coronary arteriography. I. A percutaneous transfemoral technic
29. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
30. Apolipoproteins AI and B in health and metabolic disease
31. The polymorphic paraoxonase/arylesterase isozymes of human serum
32. Plasma levels of apolipoproteins A-1 and B in Indian patients with angiographically defined coronary artery disease
33. Analysis of plasma lipids and apolipoproteins in insulin-dependent and non-insulin-dependent diabetics
34. Lipoprotein abnormalities in well-treated type II diabetic patients
35. Serum lipids, lipoproteins, and apolipoproteins and the excessive occurrence of coronary heart disease in non-insulin-dependent diabetic patients
36. HDL subparticles and coronary artery disease in NIDDM
37. HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus
38. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL
39. Plasma triglyceride determines structure-composition in low and high density lipoproteins
40. Postprandial cholesteryl ester transfer and high density lipoprotein composition in normotriglyceridemic non-insulin-dependent diabetic patients
41. Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]
42. Apoproteins B and A-I and coronary artery disease in humans
43. Clinical value of apolipoprotein measurement
44. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease
45. The response-to-retention hypothesis of early atherogenesis
46. Cellular consequences of the association of apoB ipoproteins with proteoglycans. Potential contribution to atherogenesis
47. Putting low-density lipoproteins at center stage in atherogenesis
48. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease
49. Apolipoprotein B and coronary artery disease in women: A cross-sectional study in women undergoing their first coronary angiography
50. Human serum paraoxonase/arylesterase
51. Paraoxonase genes and disease
52. Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus. The REGICOR Investigators
53. Mutations in the human paraoxonase 1 gene: Frequencies, allelic linkages and association with coronary artery disease
54. Relationship between classic risk factorsplasma antioxidants and indicators of oxidant stress in angina pectoris (AP) in Tehran